Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems
Diabetes Technology & Therapeutics · 2024-03 · 26 (3_suppl) · 102-106
DOI: 10.1089/dia.2023.0432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes Technology & Therapeutics, online erschienen am 05.02.2024. Verfasst von Halis K Akturk und 5 weiteren Autor:innen. Beteiligte Einrichtung: Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The concept of maintaining blood glucose levels within the 70–180 mg/dL range, known as time-in-range, has raised questions regarding its representation of true physiological euglycemia. Some have speculated that focusing on the time spent within the 70–140 mg/dL range, introduced as time in tight range (TITR) through the International Consensus statement, could serve as a more precise metric for assessing normoglycemia in individuals with type 1 diabetes. This article delves into the current status of TITR as an emerging marker and explores how advanced hybrid closed-loop systems may offer a promising avenue for achieving this higher level of glycemic control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Barbara Davis Center for Diabetes, University of Colorado, Aurora, Colorado, USA.
- University Medical Centre Ljubljana, and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia.
- Medtronic International Trading Sàrl, Tolochenaz, Switzerland.
ORCID-Profile: Halis K Akturk, Tadej Battelino, Tim van den Heuvel, Ohad Cohen
Zitieren
APA
Akturk, H. K., Battelino, T., Castañeda, J., Arrieta, A., van den Heuvel, T., & Cohen, O. (2024). Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems. Diabetes Technology & Therapeutics, 26(3_suppl), 102-106. https://doi.org/10.1089/dia.2023.0432
Vancouver
Akturk HK, Battelino T, Castañeda J, Arrieta A, van den Heuvel T, Cohen O. Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems. Diabetes Technology & Therapeutics. 2024;26(3_suppl):102-106. doi:10.1089/dia.2023.0432
BibTeX
@article{Akturk2024,
author = {Akturk, Halis K and Battelino, Tadej and Castañeda, Javier and Arrieta, Arcelia and van den Heuvel, Tim and Cohen, Ohad},
title = {Future of Time-in-Range Goals in the Era of Advanced Hybrid Closed-Loop Automated Insulin Delivery Systems},
journal = {Diabetes Technology & Therapeutics},
year = {2024},
volume = {26},
number = {3_suppl},
pages = {102--106},
doi = {10.1089/dia.2023.0432}
}
EUVIMED